 |
 |
 |
 |
 |
 |
 |
 |
 |
Snowdon Inc. is a pharmaceutical company that is focused on four major therapeutic areas with substantial market potential: cancer, acute and chronic pain, neurological disorders, and infectious diseases. These medical conditions cause immense suffering, economic hardship, and loss of life among millions of people every day. In each of these therapeutic areas, Snowdon has discovered prospective drug candidates that address the urgent need for safe and effective medicines. [more]
Recent News June 29, 2009: Snowdon, Inc., has been awarded a grant for $628,000 over two years by the U.S. National Institutes of Health (NIH) to develop novel therapies for Toxoplasmosis and related infectious diseases. [more] May 29, 2009: Snowdon, Inc., has been awarded a contract with the U.S. Food & Drug Administration (FDA) to develop computational tools for rapid detection of contaminants in active pharmaceutical ingredients. May 1, 2008: Snowdon, Inc., was awarded a $114,000 Phase I Small Business Innovation Research Award from the National Institutes of Health (NIH) - National Cancer Institute to support further development of the company's novel medical treatments for prostate and breast cancer. February 5, 2009: Snowdon, Inc., was notified that its milestone report for the Edison R&D grant award with the New Jersey Commission on Science & Technology (NJCST) has been approved for payment of the second installment of $166,667. [more] August 15, 2008: Snowdon, Inc., was awarded a two-year $150,000 Technology Fellowship grant by the New Jersey Commission on Science & Technology (NJCST) to support Dr. Oyenike Olabisi her research on the discovery of novel anti-cancer treatments. [more] October 11, 2007: Snowdon, Inc., was awarded a $130,000 Phase I Small Business Innovation Research Award from the National Institutes of Health (NIH) - National Institute of Neurological Disorders and Stroke (NINDS) to support further development of the company's novel therapies for the prevention and treatment of Alzheimer's and Parkinson's diseases. [more] July 9, 2007: Tiny Snowdon Bags $1 Million in Just Eight Months... The startup uses UMDNJ technology to develop a novel method for discovering drugs (NJBIZ Staff, Thomas Gaudio) [more] June 23, 2007: Snowdon, Inc., announced today that it received a two-year $500,000 Edison Innovation Award grant from the New Jersey Commission on Science & Technology (NJCST). [more] March 22, 2007: Snowdon, Inc. secured $500,000 in venture capital funding from the Foundation Venture Capital Group LLC (FVCG). [more] |
home | company overview | therapeutic areas | our technology | pipeline
about us | news | employment | contact us